Innovative therapeutics for diseases with highest unmet need
– Advanced Therapies including genetic diseases, oncology, autoimmune, cardiovascular, orphan diseases, ophthalmology, fibrosis
– In-focus indications combine unmet medical need and an increased probability of clinical success
Strong IP protection
US and Canada companies from late preclinical stage to phase 3
– It is virtually impossible to predict the effects of the drug in humans before the animal testing
Investment horizon – 3-5 years
KOL verification
– We perform comprehensive competitive analysis of relevant fields using KOL interviews and modeling future trends
Exclusion criteria
– Indications and product types with high attrition rates: neurodegenerative, infectious diseases, oligonucleotide, epigenetic drugs
– Products with lower unmet need and with lower margins: reformulations, repurposed drugs, diagnostic tests